Evidence map›Paper›PMID 41149831›Full record

ArticleJournal of personalized medicine2025

Implementation of an Alzheimer's Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study.

Mark Monane, Robert M Carlile, Kim G Johnson, Darren R Gitelman, Lawren A VandeVrede, Demetrius M Maraganore, David A Merrill, Leslie Jacobs, Justine Coppinger, Philip B Verghese and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mark MonaneC2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.ORCID 0000-0003-1550-4415
Robert M CarlilePalmetto Primary Care Physicians, Summerville, SC 29486, USA.ORCID 0009-0003-7263-3309
Kim G JohnsonDepartment of Neurology, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-8793-2489
Darren R GitelmanAdvocate Memory Center and the Advocate Aurora Research Institute, Advocate Aurora Health, Downers Grove, IL 60015, USA.ORCID 0000-0001-6057-5605
Lawren A VandeVredeMemory and Aging Center, Weill Institute for Neurology, Department of Neurology, University of California, San Francisco, CA 94158, USA.
Demetrius M MaraganoreDepartment of Neurology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
David A MerrillPacific Neuroscience Institute, Santa Monica, CA 90404, USA.
Leslie JacobsC2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.
Justine CoppingerC2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.ORCID 0009-0000-4137-930X
Philip B VergheseC2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.
Tim WestC2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.ORCID 0000-0003-3267-8249
Joel B BraunsteinC2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA.

Funding

Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosisR44AG059489 · NIA · C2N DIAGNOSTICS, LLC · PI WEST, TIM · 2018 to 2020
$2.0M
C2N Diagnostics (United States) not applicableNIA NIH HHS R44 AG059489
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer’s diseaseblood biomarkerclinical decision-makingdementiaimplementationmemory care specialistsmild cognitive impairmentpersonalized medicine

Identifiers

PMID41149831
PMCPMC12565532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.